10-K: One World Products Inc. Reports Full Year 2023 Results Amidst Restructuring

One World Products Inc. reports its full year 2023 results, highlighting a challenging year marked by a significant decrease in revenue and a net loss, while also undergoing a restructuring process in Colombia.

Summary

• One World Products Inc. reported a net loss of $3,953,321 for the year ended December 31, 2023, compared to a net loss of $3,059,477 in 2022.
• The company's revenue decreased significantly to $7,589 in 2023 from $125,662 in 2022, a 94% drop.
• Cost of goods sold also decreased to $173,122 in 2023 from $300,757 in 2022.
• The company experienced a loss on deconsolidation of foreign subsidiaries of $1,564,823.
• Operating expenses decreased to $1,915,338 in 2023 from $2,061,041 in 2022.
• The company's wholly-owned Colombian subsidiary, OWP SAS, filed for reorganization proceedings in Colombia on December 22, 2023, due to financial challenges.
• The company has deconsolidated its foreign subsidiaries until it emerges from the Reorganization Proceedings.
• The company expects to start exporting products in 2024, including CBD flower and distillate oil.

Sentiment

Score: 3

Explanation: The document presents a very negative outlook due to significant revenue decline, increased net losses, and the filing for reorganization proceedings by its Colombian subsidiary. While there are some positive aspects like strategic partnerships and future plans, the overall financial health and operational challenges overshadow them, resulting in a low sentiment score.

Positives

• The company is in the process of acquiring another Colombian subsidiary within the Bogota free trade zone.
• The company has strategic partnerships with Smokiez Edibles and Kx Family Care for distribution in Latin America.
• The company has successfully registered multiple cannabis strains with the Colombian Ministry of Health.
• The company intends to build out an extraction and production facility in the Bogota free trade zone.
• The company expects to start exporting products in 2024, including CBD flower and distillate oil.

Negatives

• The company experienced a significant decrease in revenue, dropping by 94% year-over-year.
• The company's net loss increased to $3,953,321 in 2023.
• The company's wholly-owned Colombian subsidiary, OWP SAS, filed for reorganization proceedings.
• The company has a negative working capital of $3,858,229 as of December 31, 2023.
• The company has deconsolidated its foreign subsidiaries, resulting in a loss of $1,564,823.
• The company's auditor has given a going concern qualification, questioning its ability to continue without additional financing.

Risks

• The company has a limited operating history and has generated minimal revenues.
• The company is subject to risks associated with the cannabis industry, including changes in laws and regulations.
• The company relies on Colombian licenses, authorizations, and quotas, which are subject to regulatory changes.
• The company faces competition from other companies in the cannabis business.
• The company may have difficulty establishing and maintaining bank accounts due to the nature of the cannabis industry.
• The company is subject to anti-money laundering laws and regulations.
• The company's international operations are subject to risks, including changes in regulations and currency fluctuations.
• The company is subject to product liability claims and regulatory actions.
• The company's business is subject to weather, climate change, and risks inherent in an agricultural business.
• The company may face challenges in retaining and acquiring skilled personnel.
• The company is subject to emerging market risks in Colombia, including political and economic instability.
• The company may not be able to effectively manage its growth.
• The company's stock price may be volatile due to limited trading.
• The company may issue additional stock without stockholder consent, causing dilution.
• The company is an emerging growth company and may take advantage of certain exemptions from reporting requirements.
• The company is subject to increased compliance costs as a public company.
• The company's agreements with Tysadco Partners, LLC may cause dilution and a decrease in stock price.

Future Outlook

The company expects to start exporting products in 2024, including CBD flower and distillate oil, and is developing white label commercial agreements with partners in Europe, USA, and Latin America. The company also plans to expand its product pipeline to include premium coffee, teas, and wellness products infused with CBD.

Management Comments

• Management intends to satisfy OWP SASs continuing financial obligations through the negotiation and/or settlement with creditors and the Colombian governmental authorities.
• Subject to court approval, the Company intends to continue normal operations, which consists of providing cannabinoids in bulk for the domestic and international markets, including the raw material for our brands and affiliate companies.

Industry Context

The medicinal cannabis market is characterized by growing competition and evolving regulations. The company's early entry into the market and its possession of all four Colombian licenses position it to potentially capitalize on the demand for medicinal cannabis. However, the company faces challenges in navigating the complex regulatory landscape and competing with larger, more established companies.

Comparison to Industry Standards

• The company's revenue decline of 94% is significantly worse than industry averages, which have generally seen growth in the cannabis sector.
• Companies like PharmaCielo, CannaVida, and Khiron Life Sciences Corp., which are also operating in Colombia, have reported varying degrees of success, but none have reported such a drastic revenue decline.
• The company's negative working capital of $3,858,229 is a significant concern compared to industry standards, where companies typically maintain a positive working capital to ensure operational stability.
• The filing for reorganization proceedings by OWP SAS is a major deviation from industry norms, where companies typically seek to avoid such measures.
• The company's reliance on debt financing and related party transactions is higher than industry averages, indicating a higher risk profile.

Legal Proceedings

• OWP SAS filed for protection under Colombian Law 1116 of 2006 on December 22, 2023.
• As of December 31, 2023, OWP SAS is involved in 23 separate lawsuits for various civil and labor disputes in Colombia.

Related Party Transactions

• The company has various related party transactions, including loans and compensation commitments to officers and directors.
• The company has convertible notes payable to related parties.
• The company has notes payable to related parties.
• The company has issued common stock to related parties as consideration for debt modifications.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial instability and reorganization proceedings.
• Employees may be affected by the restructuring and cost-cutting measures.
• Customers may experience disruptions in supply due to the operational challenges.
• Creditors face uncertainty regarding the recovery of their debts.
• Suppliers may be impacted by the company's financial difficulties.

Next Steps

• The company intends to continue normal operations during the Reorganization Proceeding, which consists of providing cannabinoids in bulk for the domestic and international markets.
• The company expects to start exporting products in 2024, including CBD flower and distillate oil.
• The company intends to build out an extraction and production facility in the Bogota free trade zone.
• The company will seek additional financing to fund operations.

Key Dates

Keywords

cannabis, hemp, Colombia, medical cannabis, reorganization, CBD, THC, cultivation, extraction, distillate, licenses, export, strategic partnerships, financial results